New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Sales reflect continued strong growth in oncology and vaccines
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Subscribe To Our Newsletter & Stay Updated
